MIP Diagnostics, a spinout of Leicester University which is developing molecularly imprinted polymers, has named its new CEO shortly following it securing £182,000 ($284,170).
Adrian Kinkaid, a life sciences sector veteran who previously worked as chief commercial officer for protein biotherapeutics firm Promexus, will take the helm at MIP.
Kinkaid’s first port of call at MIP will be overseeing the new influx of cash, which MIP raised through serial UK spinout investor Mercia Fund Management. The investment will be used to develop a global marketing strategy as well as further development of MIP’s technology.
Kinkaid said: “As the new CEO of MIP Diagnostics, I have the opportunity to bring an exciting cutting edge technology into the market. Furthermore, this technology has the potential to expand into different sectors, from monitoring food for contaminants, to protecting the population from the growing dangers of ‘legal highs’. The technology has a number of advantages, not least of which are robustness, speed of development and the lack of ‘cold chain’ storage requirements. It is a privilege to begin working with MIP Diagnostics, and I look forward to building a successful, dedicated team as we start expanding our impressive portfolio of products and services.”
